Abstract
Although patients with end-stage renal disease can be maintained with dialysis therapy, the superiority of patient survival with renal transplantation makes transplantation the preferred method of renal replacement. Potent immunosuppressive therapies, particularly calcineurin inhibitors, have greatly reduced the incidence of acute rejection. However, long-term allograft survival remains limited. We discuss the impact of acute rejection on long-term allograft survival and discuss other factors leading to late allograft loss, including calcineurin inhibitor toxicity, chronic allograft nephropathy, and BK virus nephropathy, as well as donor and recipient factors associated with long-term allograft loss.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 369-385 |
| Number of pages | 17 |
| Journal | Annual Review of Medicine |
| Volume | 58 |
| DOIs | |
| State | Published - 2007 |
| Externally published | Yes |
Fingerprint
Keywords
- Allograft survival
- BK virus nephropathy
- Calcineurin inhibitor toxicity
- Chronic allograft nephropathy
- Donor and recipient factors
- Kidney transplantation
ASJC Scopus subject areas
- Cell Biology
- Medicine(all)
Cite this
Why hasn't eliminating acute rejection improved graft survival? / Tantravahi, JogiRaju; Womer, Karl L.; Kaplan, Bruce.
In: Annual Review of Medicine, Vol. 58, 2007, p. 369-385.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Why hasn't eliminating acute rejection improved graft survival?
AU - Tantravahi, JogiRaju
AU - Womer, Karl L.
AU - Kaplan, Bruce
PY - 2007
Y1 - 2007
N2 - Although patients with end-stage renal disease can be maintained with dialysis therapy, the superiority of patient survival with renal transplantation makes transplantation the preferred method of renal replacement. Potent immunosuppressive therapies, particularly calcineurin inhibitors, have greatly reduced the incidence of acute rejection. However, long-term allograft survival remains limited. We discuss the impact of acute rejection on long-term allograft survival and discuss other factors leading to late allograft loss, including calcineurin inhibitor toxicity, chronic allograft nephropathy, and BK virus nephropathy, as well as donor and recipient factors associated with long-term allograft loss.
AB - Although patients with end-stage renal disease can be maintained with dialysis therapy, the superiority of patient survival with renal transplantation makes transplantation the preferred method of renal replacement. Potent immunosuppressive therapies, particularly calcineurin inhibitors, have greatly reduced the incidence of acute rejection. However, long-term allograft survival remains limited. We discuss the impact of acute rejection on long-term allograft survival and discuss other factors leading to late allograft loss, including calcineurin inhibitor toxicity, chronic allograft nephropathy, and BK virus nephropathy, as well as donor and recipient factors associated with long-term allograft loss.
KW - Allograft survival
KW - BK virus nephropathy
KW - Calcineurin inhibitor toxicity
KW - Chronic allograft nephropathy
KW - Donor and recipient factors
KW - Kidney transplantation
UR - http://www.scopus.com/inward/record.url?scp=34047171006&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34047171006&partnerID=8YFLogxK
U2 - 10.1146/annurev.med.58.061705.145143
DO - 10.1146/annurev.med.58.061705.145143
M3 - Article
C2 - 17002551
AN - SCOPUS:34047171006
VL - 58
SP - 369
EP - 385
JO - Annual Review of Medicine
JF - Annual Review of Medicine
SN - 0066-4219
ER -